Tenax Therapeutics Achieves Key Milestones in Phase 3 Trials and Reports Full Year 2025 Financial Results

Overview

Tenax Therapeutics, Inc. (Nasdaq: TENX), a late-stage biopharmaceutical company focused on novel cardiopulmonary therapies, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company also provided significant corporate updates, including major progress in its clinical development program for TNX-103, a potential first-in-class oral therapy for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).

Key Highlights and Potentially Price-Sensitive Developments

• LEVEL Study Reaches Randomization Target: Tenax achieved its target of randomizing 230 patients in the pivotal Phase 3 LEVEL study for TNX-103. The screening period for LEVEL has closed, and all patients currently in screening will have the opportunity to complete randomization, expected by the end of March 2026. Topline data from this trial are anticipated in the third quarter of 2026—a potentially significant catalyst for the company’s valuation.
• Global Expansion with LEVEL-2 Trial: The Company initiated a second global, registrational Phase 3 clinical trial (LEVEL-2) for TNX-103 in PH-HFpEF patients in December 2025. Enrollment for LEVEL-2 is expected to complete by the end of 2027, demonstrating Tenax’s commitment to rapidly advancing its clinical pipeline and broadening its market reach.
• Open-Label Extension (OLE) Study: An OLE study has been opened to provide all participants in LEVEL and LEVEL-2 continued access to TNX-103 until commercial availability, a move that may enhance patient retention and data continuity.
• Promising BSSR Results: A prespecified Blinded Sample Size Re-estimation (BSSR) conducted in December 2025 confirmed the LEVEL trial is powered at well over 90% to detect a 25-meter change in 6-minute walk distance, supporting robust trial design and likelihood of statistically meaningful results.
• Intellectual Property Expansion: In January 2026, the U.S. Patent and Trademark Office issued a Notice of Allowance further protecting Tenax’s subcutaneous formulation of levosimendan across a broad range of cardiovascular indications, including PH-HFpEF and related diseases. This strengthens Tenax’s competitive position and potential market exclusivity.

Financial Results for Q4 and FY 2025

• Cash Position: As of December 31, 2025, Tenax reported cash and cash equivalents totaling \$97.6 million. Management expects this to fund operations through 2027, reducing near-term financing risk.
• R&D Expenses: Research and development expenses surged to \$10.5 million in Q4 2025 (up from \$4.6 million in Q4 2024) and reached \$32.7 million for the full year 2025 (compared to \$12.7 million in 2024). The increase reflects accelerated investment in ongoing and new Phase 3 trials, as well as higher personnel and compensation costs linked to clinical expansion.
• G&A Expenses: General and administrative expenses increased to \$5.9 million in Q4 2025 (up from \$2.7 million in Q4 2024) and \$23.7 million for the full year (vs. \$6.8 million in 2024), mainly due to increased stock-based compensation and professional fees.
• Net Loss: Tenax’s net loss widened to \$15.5 million for Q4 2025 (vs. \$6.3 million in Q4 2024) and \$52.6 million for the year (up from \$17.6 million in 2024). While losses increased, this reflects the company’s aggressive clinical advancement strategy.

Pipeline and Market Opportunity

Levosimendan (TNX-101, TNX-102, TNX-103) is a first-in-class K-ATP channel activator and calcium sensitizer. It is not currently approved in the US or Canada but is authorized for acute heart failure in 60 countries. Tenax’s focus is on developing oral TNX-103 for PH-HFpEF, an area with no approved therapies and significant unmet medical need.

The company’s Phase 2 HELP study and its open-label extension have shown promising improvements in exercise capacity and quality of life for PH-HFpEF patients, further supporting the clinical rationale for late-stage development.

Upcoming Catalysts

• Completion of randomization in LEVEL study (expected by end of March 2026).
• Topline data readout from LEVEL in Q3 2026, which could be highly price-sensitive depending on results.
• Continued enrollment and global site activation for LEVEL-2, with completion anticipated by end of 2027.
• Potential further IP developments and regulatory interactions.

Risks and Considerations

Investors should note Tenax’s forward-looking statements include risks typical for clinical-stage companies, including clinical trial timing, regulatory approval uncertainties, reliance on third parties, market dynamics, intellectual property security, and macroeconomic risks.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.

View TENAX THERAPEUTICS, INC. Historical chart here